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heterozygous missense mutation in IRF6 (Pro456Ser). 
p.Arg233Cys was reported as extremely rare in exome data-
bases (1 allele out of 120.852 alleles sequenced), strictly 
conserved among species and was predicted deleterious by 
all variant predictor programs. Pro456Ser was predicted 
to be benign. MLPA did not reveal any exon deletions or 
duplications in any of the patients.
Conclusion This is the first report of IRF6 analysis in an 
IGHD cohort. We found one new mutation which, based on 
in silico analysis, could be of functional relevance. How-
ever, we did not find any mutations in the other patients. 
Therefore, we conclude that IRF6 defects are rare in IGHD 
patients and further research should focus on new candidate 
genes.
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Abbreviations
AP  Anterior pituitary
CLP  Cleft lip and palate
CP  Cleft palate alone
EPP  Ectopic posterior pituitary
GH  Growth hormone
GHD  Growth hormone deficiency
HAP  Hypoplastic anterior pituitary
HSDS  Height SDS
IGF-I  Insulin-like growth factor-I
IGHD  Idiopathic GHD
IRF6  Interferon regulatory factor 6
MLPA  Multiplex ligation-dependent probe 
amplification
NSCL/P  Non-syndromic cleft lip and/or palate
PP  Posterior pituitary
PPS  Popliteal pterygium syndrome
Abstract 
Introduction Growth hormone is secreted by the pitui-
tary gland, which forms part of the craniofacial midline. 
IRF6 encodes a transcription factor involved in the devel-
opment of the craniofacial midline and mutations in IRF6 
are known to disturb craniofacial development. Crani-
ofacial and pituitary development are closely related. After 
whole exome sequencing revealed a new mutation in IRF6 
in a family with Idiopathic Growth Hormone Deficiency 
(IGHD), we screened the remainder of our IGHD cohort 
for mutations in this gene and related their genotypes to 
pituitary and craniofacial morphology.
Materials and methods We sequenced all coding exons 
and exon–intron boundaries of IRF6 in 81 patients with 
IGHD. We performed a multiplex ligation-dependent probe 
amplification (MLPA) in order to exclude copy number 
variations in IRF6. We analyzed facial measurements taken 
from standardized digital pictures of 48 patients.
Results We found two new variants and eleven poly-
morphisms. Apart from the new mutation found in the 
index family (p.Arg233Cys), we found one other new 
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SDS  Standard deviation score
SNP  Single nucleotide polymorphism
VWS  Van der Woude syndrome
Introduction
Growth hormone (GH) is secreted by the pituitary gland, 
which forms part of the craniofacial midline. Growth Hor-
mone Deficiency (GHD) is the result of insufficient GH 
secretion, resulting in decreased production of GH-depend-
ent growth factors. The incidence of Idiopathic GH Defi-
ciency (IGHD) is estimated to vary between 1 in 3500 to 1 
in 10,000 live births [1–5]. Estimates indicate that between 
5 and 30% of idiopathic IGHD case have first-degree rela-
tives with short stature, suggesting a genetic etiology [6].
Although mutations in GH1 and GHRHR can cause 
IGHD [7–10], the vast majority of patients with IGHD do 
not carry mutations in these two genes. This suggests that 
other genes are involved. The identification of these genes 
is needed to understand the pathogenesis of this complex 
condition.
Pituitary hormone deficiencies have been associated 
with defects in the craniofacial midline. Several authors 
have reported associations between pituitary problems and 
craniofacial defects [11–17]. Studies investigating hormone 
deficiencies in larger cohorts of patients with craniofacial 
clefting show remarkable results. Traggiai et al. studied 19 
patients with cleft lip and palate and found GH deficiency 
in seven of them (37%) [17]. Akin et  al. [18] studied 33 
patients with median orofacial clefts and found endocrine 
abnormalities in 22 (70.9%), of which 13 had single and 
nine multiple hormone deficiencies. Growth hormone defi-
ciency was detected in four of them (12%). There was no 
relationship between the types of orofacial cleft and endo-
crine abnormalities. Slavotinek et al. reviewed 31 patients 
with pituitary duplication. In 19 of them (61%), pituitary 
duplication was accompanied by cleft palate [19]. Another 
well-known association between pituitary problems and 
craniofacial midline defects is called septo-optic dysplasia, 
defined as the absence of the septum pellucidum combined 
with hypoplasia of the optic nerve and pituitary dysfunc-
tion [20, 21].
Also in patients with Isolated GH Deficiency (IGHD), 
a broad range of craniofacial midline abnormalities have 
been described, like hypertelorism, cleft lip and palate and 
single median maxillary central incisor [22, 23]. The mech-
anism underlying this association between isolated GH 
deficiency and craniofacial midline defects is still poorly 
understood.
Apart from the association between pituitary function 
and craniofacial features, we also found an association 
between pituitary morphology and craniofacial features 
[24].
All these findings are suggestive of an association 
between craniofacial midline and pituitary development. 
The mechanism underlying this association has not yet 
been elucidated.
An important gene involved in craniofacial midline 
formation is IRF6 on chromosome 1q32.2. IRF6 encodes 
Interferon Regulatory Factor 6, a transcription factor 
expressed in oral and nasal epithelia. IRF6 regulates the 
proliferation and differentiation of epithelial cells during 
the formation of the craniofacial midline during embryonic 
development [25]. Mutations in IRF6 are associated with 
Van der Woude Syndrome (VWS, OMIM #119300) and 
Popliteal Pterygium Syndrome (PPS, OMIM #119500). 
Both syndromes are characterized by a cleft lip and/or 
cleft palate, which are due to defective craniofacial devel-
opment. Whereas mutations in IRF6 cause syndromic oro-
facial clefting, IRF6 polymorphisms are associated with 
non-syndromic cleft lip and/or palate (NSCL/P, OMIM 
#119530) [26].
Whole exome sequencing (WES) revealed an IRF6 
mutation in one of the families of our IGHD cohort. Since 
IRF6 mutations are known to disturb craniofacial develop-
ment, which is related to pituitary development, we con-
sidered IRF6 a possible candidate gene for IGHD. Further-
more, we hypothesized that variations in IRF6 might be 
related to craniofacial morphology. The relation between 
IRF6 and pituitary function, pituitary morphology and 
craniofacial features has not been studied before.
Materials and methods
Study subjects
We studied 81 patients with IGHD participating in the 
Dutch HYPOPIT study, which investigates the genetic 
causes of idiopathic GH deficiency. These patients had been 
recruited from the Endocrinology Departments at six uni-
versity and two non-university hospitals, and had been reg-
istered in the Dutch National Registry of Growth Hormone 
Treatment between 1992 and 2003. IGHD was defined as a 
peak GH response <6.7 µg/L during Growth Hormone test 
(mostly arginine tests), or <10 µg/L combined with serum 
IGF-I < −2 SDS (Standard Deviation Score, according to 
age- and gender-specific values) and normal serum levels 
of other pituitary hormones. Exclusion criteria were: GH 
deficiency of known cause, such as a brain tumor, brain 
surgery, brain radiation or known syndromes. We obtained 
approval from the medical ethics committees of all partici-
pating hospitals. Informed consent was obtained from all 
participants and their parents if they were less than 18 years 
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old. 81 IGHD patients who were treated in the participating 
hospitals and who fulfilled the criteria for IGHD, agreed to 
participate in the study. All patients received GH treatment. 
Clinical data of the patients had previously been collected 
from the Dutch National Registry of Growth Hormone 
Treatment. GH1 and GHRHR mutations had been ruled out 
in all patients. MRI reports were available for 67 patients.
DNA analysis
DNA of 81 patients with IGHD was isolated from whole 
blood collected in EDTA tubes using standard procedures. 
We made dilutions of 25  µl/ng of all the collected DNA 
samples and stored them in a 96-wells plate at −20 °C.
Whole exome sequencing
DNA samples of the index patient and his first-degree rela-
tives was analyzed by Whole Exome Sequencing: Nimble-
gen SeqCap EZ Exome v2.0 44  Mb in combination with 
Illumina Paired-End Library Preparation and 2  ×  100  bp 
Sequencing at 4  Gb per sample. Additional analysis was 
done with Illumina Human CytoSNP850K SNP arrays.
IRF6 Sequencing
After WES revealed the IRF6 mutation in the index fam-
ily, we screened the remaining 80 IGHD patients for IRF6 
defects as well. For all patients, we amplified coding 
exons and exon–intron boundaries by PCR, using prim-
ers described by Wang et al. [36]. For exons 3, 4, 8 and 9 
we designed new primers using the program Primer3 (ref-
erence sequence NM_006147.3). Primers sequences are 
shown in supplementary Table S1. For PCR, we used the 
following Qiagen reagents: 10x PCR buffer, 0.2 mM dNTP 
mixture and 5 units/μl Taq DNA Polymerase. For the prim-
ers used to amplify exon 4, we also added 0.5 μl 25 mM 
MgCl. For primer pairs 1, 2, 5, 6, 7a, 7b, 9a and 9c, we 
used the standard PCR program. For primer pairs 3, 4, 8 
and 9b, we used a Touch Down PCR, lowering the anneal-
ing temperature one degree per cycle, during the first ten 
cycles. PCR reagents and detailed amplification programs 
are shown in supplementary Tables S2 and S3. After gel 
electrophoresis, we purified the PCR products using the 
High Pure PCR product Purification kit (Qiagen) or the 
Illustra GFX 96 PCR Purification Kit (GE Healthcare) 
according to the supplied protocols. Sequencing was out-
sourced to Baseclear Sequencing Services (www.baseclear.
com) and carried out using the ABI3730XL sequencer 
(Life Technologies). The results were analyzed for muta-
tions using Sequencher4.1 (Genecards). For each new vari-
ant, the Variant Effect Predictor (www.Ensembl.org) was 
consulted to predict functional impact. The predictions of 
this tool are based on the structure and function of the pro-
tein and the degree of conservation.
Multiplex ligation‑dependent probe amplification
Copy number analysis was performed using Multi-
plex Ligation-dependent Probe Amplification (MLPA). 
We used SALSA MLPA EK1 reagent and P304 IRF6 
probemix according to the protocol of MRC-Holland. 
We analyzed the results with the program Genemarker 
(SOFTGENETICS).
Craniofacial measurements
For the current analysis, we measured Canthal Index (CI) 
from digital photographs taken previously [24]. Frontal and 
lateral digital photographs were taken under standardized 
conditions in order to obtain comparable images of reliable 
quality. Pictures were taken using a  Canon® 4.0 Megapixel 
digital camera. A squared background plate was used to 
position pictures parallel to the lower extreme of the com-
puter screen, according to the method used by Bishara [27]. 
Pictures were taken in 48 patients, 4 patients were excluded 
because of suboptimal quality due to movement artefacts. 
Adobe Photoshop was used for morphometric analysis. 
Facial measurements of all pictures were performed by an 
independent observer (JB). The landmarks we used were 
those described by Farkas [28] (Fig. 1). Horizontal and ver-
tical lines were drawn and distance between the lines were 
measured.
Statistical analysis
We used SPSS 22.0 to analyze craniofacial measurements 
in relation to growth-related parameters (GH levels dur-
ing arginine testing, IGF-I SDS and height SDS at start 
GH). We used one way ANOVA and Chi square analysis 
to assess differences in clinical parameters according to 
genotype.
Results
The IRF6 mutation found in the index family is a heterozy-
gous missense mutation in exon 7, encoding part of the 
protein binding domain of IRF6. The substitution of the C 
by a T at this position (c.697C>T) results in an amino acid 
change of Arginine to Cysteine (p.Arg233Cys). The muta-
tion was found in a GH deficient boy with non-consanguin-
eous parents. His father’s height was 182 cm (0.1SD) and 
his mother’s height was 160  cm (−1.2 SD). His younger 
brother and sister had growth retardation as well, but they 
were not GH deficient. The boy was born after 39 weeks 
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of pregnancy and was small for gestational age (2400 
and 47  cm). He suffered neonatal jaundice for which he 
received phototherapy. His arginine test showed a peak GH 
of 1.7 µg/L, glucagon test showed a peak GH of 2.5 µg/L 
and his IGF-I SDS before start of GH was −1.4. He did not 
have any other pituitary hormone deficiencies. At start of 
GH treatment his height SDS was −2.4. At that time, his 
bone age was 2 years delayed. He did not have any midline 
defect and his pituitary MRI was normal. He responded 
very well to GH therapy; his height SDS increased with 
2 SDS and his IGF-I increased from −1.4 to 0.4 SDS. 
p.Arg233Cys is reported as extremely rare in exome data-
bases (1 allele out of 120.852 alleles sequenced). Multi-
ple species amino acid sequence alignment showed that 
arginine at AA position 233 is conserved in many differ-
ent species (overview of species available upon request). 
The Variant Effect Predictor showed this mutation is del-
eterious. After finding p.Arg233Cys in the index case, we 
sequenced both parents, the brother and the sister and found 
that the mother also carried the mutation (Fig.  2). The 
mother’s phenotype was normal. However, apart from the 
new mutation p.Arg233Cys, the mother carried the minor 
allele of rs2235371. Rs2235371 is a polymorphism known 
to protect against orofacial cleft formation. Figure 2 shows 
the genotypes for the new mutation p.Arg233Cys and the 
protective SNP rs2235371, as well as phenotypic data for 
the index patient and his first-degree relatives. As seen in 
this figure, the only person with IGHD is the only person 
with the new mutation p.Arg233Cys without the protective 
SNP rs2235371 (see also "Discussion" section).
After finding this new mutation in IRF6 in the index 
family, we screened another 80 patients with IGHD and 
Fig. 1  Anthropometric 
landmarks for frontal facial 
photographs carried out in our 
patients
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we found one more new mutation and 11 known poly-
morphisms in IRF6 (Table  1). MLPA did not show any 
copy number variations. The genotype distributions of 
the known IRF6 SNPs in our cohort were consistent with 
Hardy–Weinberg equilibrium (data not shown) and not 
significantly different from those in European control 
cohorts (www.ensembl.org).
The other new mutation, p.Pro456Ser was found in a boy 
diagnosed as GH deficient at the age of 9 years and started 
GH treatment when his height SDS was −3.8. He did not 
Fig. 2  Genotypic and phenotypic data of the family with the new mutation p.Arg233Cys. For each individual, phenotype and presence or 
absence of the new mutation (p.Arg233Cys) and the protective SNP (p.Val274Ile,rs2235371) is shown
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have any other pituitary hormone deficiencies. Exome data-
bases showed that Pro456Ser was also rare, but the muta-
tion is not strictly conserved among species and predicted 
to be benign (not damaging). His unaffected father also car-
ried this mutation (data not shown).
Figure  3 shows IRF6 variants previously described in 
the literature, as well as the new IRF6 mutations found in 
the current study. Apart from the two new mutations, we 
found 11 known polymorphisms. We focused on rs2235371 
(V274I), which has been reported to be protective against 
orofacial cleft formation (see also “Discussion” section). 
The clinical characteristics of our patient cohort accord-
ing to rs2235371 genotype are shown in Table 2. Patients 
carrying the protective minor (A) allele showed a trend 
towards a less severe phenotype, which was consistent 
for all clinical parameters measured: they had a higher 
GH peak during arginine testing, a larger height SDS and 
a higher IGF-1 SDS at start of GH treatment. Mid-facial 
hypoplasia, a facial characteristic often seen in patients 
with severe GHD, was also less often seen in patients 
with the protective minor allele. None of the patients 
with the protective allele had orofacial clefts, whereas of 
the 76 patients without the protective allele, two had oro-
facial clefts (one female patient had a cleft lip and palate 
and one male patient had a cleft lip and palate and bifid 
tongue). Pituitary anomalies on MRI were absent among 
the patients with the protective allele, whereas they were 
present in 51% of the patients without the protective allele 
(0% vs. 51% p = 0.017) (Table 3). Although the milder phe-
notype was clear for all clinical parameters measured, only 
the difference in MRI results reached statistical significance 
(p = 0.017).
Craniofacial measurements were not related to 
rs2235371 genotype.
As expected, there were slight differences between 
males and female craniofacial features. Craniofacial meas-
urements according to sex are shown in Table 4.
Discussion
We studied IRF6 as a new candidate gene for Idiopathic 
Growth Hormone Deficiency, based on literature data and 
on Exome Sequencing results of one family of our IGHD 
cohort. In 81 IGHD patients, we found two new mutations, 
of which one has a possible deleterious effect.
Table 1  Known and new 
variants found in the IRF6 gene 
in our IGHD cohort
Variants printed in bold are discussed in the “Discussion” section
Exon SNP ID Position Impact Base change AA change
1 rs34743335 5′upstream c.-313T>A
rs12403006 5′UTR c.-302A>T
2 rs2235377 Intronic c.-75-4A>G
rs861019 5′UTR c.-73T>C
3 No variants found
4 rs7552506 Intronic c.175-5C>G
5 rs2013162 Exonic Silent c.459G>T p.Ser58=
6 No variants found
7 New mutation Exonic Missense c.697C>T p.Arg233Cys
rs2235371 Exonic Missense c.820G>A p.Val274Ile
rs41303263 Exonic Silent c.759T>C p.Tyr158=
rs2235373 c.1060+37C>T
8 No variants found
9 New mutation Exonic Missense c.1366C>T p.Pro456Ser
rs17317411 3′UTR c.*451A>G
rs75012801 3′UTR c.*479T>G
Fig. 3  Overview of IRF6 variants reported in the literature. Num-
bers above the exons indicate mutations found in patients with PPS, 
number underneath the exons indicate mutations found in patient with 
VWS. The grey boxes represent non-coding parts of IRF6. Exons 3 
and 4 (dotted) encode the DNA-binding domain whereas exons 7 and 
8 (striped) encode the protein-binding domain. The two arrows indi-
cate the new mutations found in the current cohort
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IRF6 is a transcriptional activator, which belongs to 
a family of nine transcription factors that share a highly 
conserved DNA binding domain and a less conserved pro-
tein-binding domain [29]. Defects in IRF6 can prevent the 
expression of a large number of genes directly controlled 
by IRF6, listed by Bottia et al. [30].
The new mutation we found in the index family, 
p.Arg233Cys, is located in the protein-binding domain 
of IRF6. The Arginine residue at position is conserved in 
many different species (overview of species available upon 
request), suggesting functional importance. The introduc-
tion of a cysteine residue in the protein could cause forma-
tion of a disulfide bond, which is likely to affect protein 
stability. This supports the prediction of Ensembl’s Variant 
Effect Predictor that the new mutation p.Arg233Cys is del-
eterious. Apart from the index case, his mother also car-
ried the p.Arg233Cys variant. Interestingly, the mother had 
a normal phenotype. However, the mother also carried the 
protective allele of rs2235371 (V274I), whereas the index 
case did not. Rs2235371 (V274I) affects a highly conserved 
Valine in the protein-binding domain of IRF6, replacing 
it with Isoleucine [31]. Although some authors conclude 
otherwise [32], the vast majority of studies conclude that 
rs2235371 has an independent protective effect on orofa-
cial cleft formation [33–37]. The only person in this fam-
ily with GH deficiency was the boy with the new mutation 
p.Arg233Cys without the protective SNP rs2235371. Our 
hypothesis is that rs2235371 might also have a protective 
effect on the IGHD phenotype in this family. Although the 
functional impact of p.Arg233Cys remains to be confirmed, 
its effect might be counteracted by the protective rs2235371 
allele. Further research should include functional analyses 
Table 2  Clinical data of our patients according to IRF6 rs2235371 
genotype
GHD growth hormone deficiency
Significant differences (between people with and without the protec-
tive SNP) are shown in bold
a Midfacial hypoplasia reported by treating physician, before start of 
GH treatment
b One female patient had a cleft lip and palate, one male patient had a 
cleft lip and palate and a bifid tongue
IRF6 rs2235371
G/G G/A Total p
Sex
 F/M 24/52 1/4 81 0.63
Height at start GH
 Mean ± SD −3.2 ± 0.8 −2.9 ± 0.7 81 0.45
 Range (−5.8 to −0.7) (−3.7 to −2.1)
Arginin test peak GH
 Mean ± SD 9.5 ± 6.3 11.5 ± 2.7 65 0.53
 Range (0–24) (8.8–15)
IGF-I SDS
 Mean ± SD −3.2 ± 2.4 −2.6 ± 1.5 73 0.55
 Range (−9.0 to 0.9) (−5.0 to −1.1)
Birth weight (kg)
 Mean ± SD 3.1 ± 0.6 2.8 ± 0.5 78 0.25
 Range (1.2–4.3) (2.1–3.2)
Birth length (cm)
 Mean ± SD 48 ± 3.5 45.5 ± 4.2 60 0.18
 Range (35–52) (41–50)
Gestational age at birth (w)
 Mean ± SD 38.9 ± 2.8 38.9 ± 1.3 76 0.94
 Range (32–43) (37–40)
Pituitary anomalies on MRI
 No 24 (31%) 4 (80%) 81 0.017
 Yes 39 (51%) 0 (0%)
 Unknown 13 (17%) 1 (20%) 
Midfacial  hypoplasiaa
Yes 9 (12%) 0 (0%) 81 0.414
No 67 (88%) 5 (100%)
Midline  defectb
Yes 2 (3%) 0 (0%) 81 0.713
No 74 (97%) 5 (100%)
Table 3  Pituitary morphology in our patients, according to IRF6 
SNP rs2235371 genotype
EPP ectopic posterior pituitary, AP anterior pituitary
a G/G versus G/A: p = 0.017
b MRI not available
c One patient had an ‘abnormal form’ of the pituitary (not otherwise 
specified), the other had a hypodense area within the pituitary
rs2235371 genotype
G/G G/A
Normal pituitary 24 (31%)a 4 (100%)a
 MRI 22 4
 CTb 2 0
Abnormal pituitary (MRI) 39 (51%)a 0 (0%)a
 Classic triad 2 0
 Other pituitary anomalies on  MRIc 2 0
 Aplastic AP 1 0
 (Partial) empty sella 2 0
 EPP, invisible AP 1 0
 EPP, AP not described 1 0
 EPP, normal AP 8 0
 EPP, small AP 8 0
 AP small, PP small 6 0
 AP small, PP invisible 3 0
 AP small, PP and stalk normal 5 0
 No pituitary imaging available 13 (17%) 1 (20%)
Total 76 5
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to characterize the effect of the new mutation, also in com-
bination with the protective SNP.
Defects in the craniofacial midline are associated with 
deficiencies of pituitary hormones, like GH [11–17]. GH 
deficiency was found in 37% of patients with cleft lip and 
palate [17]. Although one might expect to find combined 
pituitary hormone deficiencies in patients with midline 
defects, Akin et  al. [18] found isolated pituitary hormone 
deficiency in 13 of 33 patients with median orofacial clefts. 
GH deficiency was detected in four of the patients (12%). 
The mechanism underlying the association between crani-
ofacial midline defects and GH deficiency has not yet been 
elucidated.
In our study, we found associations which, prudently, 
might be interpreted as a protective effect of the rs2235371 
minor allele on IGHD phenotype. This is in line with lit-
erature findings showing an independent protective effect 
of rs2235371 on orofacial cleft formation. In our cohort, 
patients carrying the minor allele for rs2235371 had a 
slightly less severe phenotype. This was consistent for all 
clinical parameters measured: they had a larger height SDS 
at start of GH treatment, higher GH peak during arginine 
testing, higher IGF-1 SDS at start of GH treatment, no 
pituitary anomalies on MRI and less mid-facial hypoplasia 
(a facial characteristic often seen in patients with severe 
GHD). However, since patient numbers are small, p values 
were not below 0.05 and therefore we cannot draw any firm 
conclusions from this.
Miller et  al. [38] reported that IRF6 SNP rs2235371 
was related to craniofacial measurements. However, we did 
not find any association between rs2235371 genotypes and 
craniofacial measurements.
To our knowledge, this is the first study investigating 
IRF6, a gene involved in craniofacial midline formation, in 
Table 4  Facial measurements 
of our patients according to sex 
#=mean of left and right lateral 
photographs
N Mean SD Minimum Maximum p
Canthal index (enen/exex)
 Male 36 0.38 0.04 .31 .55 0.051
 Female 15 0.36 0.02 .32 .39
 Total 51 0.37 0.03 .31 .55
Eye width (exen/exex #)
 Male 36 0.31 0.02 .28 .37 0.047
 Female 15 0.32 0.01 .30 .33
 Total 51 0.31 0.02 .28 .37
Nose width (alal/exex)
 Male 36 0.42 0.04 .36 .55 0.493
 Female 15 0.42 0.03 .35 .46
 Total 51 0.42 0.04 .35 .55
Mouth width (chch/exex)
 Male 34 0.56 0.07 .39 .73 0.240
 Female 12 0.59 0.05 .48 .66
 Total 46 0.57 0.07 .39 .73
Forehead height (trn/trls #)
 Male 23 0.51 0.05 .41 .59 0.054
 Female 7 0.55 0.03 .50 .60
 Total 30 0.52 0.05 .41 .60
Nose length (nsn/trls #)
 Male 23 0.37 0.05 .31 .48 0.225
 Female 7 0.35 0.03 .28 .38
 Total 30 0.37 0.04 .28 .48
Philtrum length (snls/trls #)
 Male 23 0.11 0.02 .09 .15 0.074
 Female 7 0.10 0.02 .08 .12
 Total 30 0.11 0.02 .08 .15
Ear length (sasba/trls #)
 Male 21 0.48 0.04 .42 .56 0.120
 Female 6 0.51 0.02 .48 .53
 Total 27 0.48 0.04 .42 .56
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relation to facial and pituitary morphology of patients with 
idiopathic growth hormone deficiency. Although the muta-
tion p.Arg233Cys might have functional impact and thus be 
a rare cause of IGHD, the majority of patients in our cohort 
did not have any defects in IRF6. We therefore conclude 
that IRF6 defects are rare in IGHD patients and further 
research should focus on other genes.
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